West Pharmaceutical Services Retained Earnings increased by 2.3% to $4.48B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.0%, from $4.03B to $4.48B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows an upward trend with a 18.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
retained_earnings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.16B | $2.34B | $2.46B | $2.62B | $2.79B | $2.91B | $2.99B | $3.11B | $3.25B | $3.42B | $3.52B | $3.62B | $3.72B | $3.86B | $3.96B | $4.03B | $4.14B | $4.26B | $4.37B | $4.48B |
| QoQ Change | — | +8.1% | +5.2% | +6.5% | +6.7% | +4.3% | +2.6% | +4.2% | +4.5% | +5.0% | +3.1% | +2.9% | +2.7% | +3.7% | +2.6% | +1.9% | +2.7% | +3.0% | +2.6% | +2.3% |
| YoY Change | — | — | — | — | +29.3% | +24.7% | +21.6% | +19.0% | +16.5% | +17.3% | +17.9% | +16.4% | +14.3% | +12.9% | +12.3% | +11.2% | +11.2% | +10.5% | +10.6% | +11.0% |